{"entity":{"id":"nct06547736","kind":"trial","name":"Exploratory Platform Research on Precision Therapy of Advanced Pancreatic Cancer","aka":[],"tldr":"A phase 2 trial of adebrelimab in pancreatic cancer, run by Fudan University, now recruiting.","summary":"Exploratory Platform Research on Precision Therapy of Advanced Pancreatic Cancer is a phase 2, interventional study registered as NCT06547736 by Fudan University, with a registry enrolment figure of 160 participants, started 2024-10-14 and due to reach its primary completion in 2027-03. Interventions recorded: SHR-A2102 or/and HRS-4642; SHR-A1904 or/and HRS-4642; SHR-A1811 or/and HRS-4642; SHR-A2102, HRS4642 and Adebrelimab. Conditions listed: Pancreatic Cancer. Primary outcome: Recommended phase II dose (RP2D); Objective Response Rate (ORR). Pancreatic eligibility wording from the registry: \"Advanced (metastatic or unresectable) pancreatic cancer; and subjects must have at least one measurable lesion as defined by RECIST v1\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06547736","url":"https://clinicaltrials.gov/study/NCT06547736"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["locally-advanced-pdac","metastatic-pdac"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["adebrelimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06547736","phase":"2","setting":"A Single-center, Open-label, Exploratory Platform Research on Precision Therapy of Advanced Pancreatic Cancer","sponsor":"Fudan University","enrolled":160,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06547736/","neighbours":{"cancer":[{"id":"locally-advanced-pdac","kind":"cancer","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","route":"/cancers/locally-advanced-pdac/"},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"adebrelimab","kind":"drug","name":"Adebrelimab","route":"/drugs/adebrelimab/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}